Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0003092
UniProt IDP04637
Primary gene name(s)TP53
Synonym gene name(s)P53
Protein nameCellular tumor antigen p53
Protein functionActs as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21, lincRNA-p21 and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2, PubMed:24051492. {ECO:0000269|PubMed:11025664, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:15186775, ECO:0000269|PubMed:15340061, ECO:0000269|PubMed:17317671, ECO:0000269|PubMed:17349958, ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:20673990, ECO:0000269|PubMed:20959462, ECO:0000269|PubMed:22726440, ECO:0000269|PubMed:24051492, ECO:0000269|PubMed:9840937}.
Subcellular locationCytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Note=Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2. Translocates to mitochondria upon oxidative stress.;
SUBCELLULAR LOCATION: Isoform 1: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.;
SUBCELLULAR LOCATION: Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.;
SUBCELLULAR LOCATION: Isoform 3: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.;
SUBCELLULAR LOCATION: Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.;
SUBCELLULAR LOCATION: Isoform 7: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.;
SUBCELLULAR LOCATION: Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.;
SUBCELLULAR LOCATION: Isoform 9: Cytoplasm.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P04637
Gene Ontology
(Biological Process)
Complete annatation
base-excision repair [GO:0006284];
cell aging [GO:0007569];
cell cycle arrest [GO:0007050];
cell differentiation [GO:0030154];
cell proliferation [GO:0008283];
cellular protein localization [GO:0034613];
cellular response to DNA damage stimulus [GO:0006974];
cellular response to drug [GO:0035690];
cellular response to glucose starvation [GO:0042149];
cellular response to hypoxia [GO:0071456];
cellular response to ionizing radiation [GO:0071479];
cellular response to UV [GO:0034644];
chromatin assembly [GO:0031497];
circadian behavior [GO:0048512];
determination of adult lifespan [GO:0008340];
DNA damage response, signal transduction by p53 class mediator [GO:0030330];
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest [GO:0006977];
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator [GO:0006978];
DNA strand renaturation [GO:0000733];
entrainment of circadian clock by photoperiod [GO:0043153];
ER overload response [GO:0006983];
intrinsic apoptotic signaling pathway [GO:0097193];
intrinsic apoptotic signaling pathway by p53 class mediator [GO:0072332];
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:0042771];
mitotic G1 DNA damage checkpoint [GO:0031571];
multicellular organism development [GO:0007275];
negative regulation of apoptotic process [GO:0043066];
negative regulation of cell growth [GO:0030308];
negative regulation of cell proliferation [GO:0008285];
negative regulation of fibroblast proliferation [GO:0048147];
negative regulation of helicase activity [GO:0051097];
negative regulation of telomerase activity [GO:0051974];
negative regulation of transcription, DNA-templated [GO:0045892];
negative regulation of transcription from RNA polymerase II promoter [GO:0000122];
nucleotide-excision repair [GO:0006289];
oligodendrocyte apoptotic process [GO:0097252];
oxidative stress-induced premature senescence [GO:0090403];
positive regulation of apoptotic process [GO:0043065];
positive regulation of cell cycle arrest [GO:0071158];
positive regulation of execution phase of apoptosis [GO:1900119];
positive regulation of gene expression [GO:0010628];
positive regulation of histone deacetylation [GO:0031065];
positive regulation of intrinsic apoptotic signaling pathway [GO:2001244];
positive regulation of neuron apoptotic process [GO:0043525];
positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731];
positive regulation of protein export from nucleus [GO:0046827];
positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway [GO:1900740];
positive regulation of protein oligomerization [GO:0032461];
positive regulation of reactive oxygen species metabolic process [GO:2000379];
positive regulation of release of cytochrome c from mitochondria [GO:0090200];
positive regulation of thymocyte apoptotic process [GO:0070245];
positive regulation of transcription, DNA-templated [GO:0045893];
positive regulation of transcription from RNA polymerase II promoter [GO:0045944];
positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress [GO:1990440];
proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161];
protein complex assembly [GO:0006461];
protein localization [GO:0008104];
protein sumoylation [GO:0016925];
protein tetramerization [GO:0051262];
Ras protein signal transduction [GO:0007265];
regulation of apoptotic process [GO:0042981];
regulation of cell cycle G2/M phase transition [GO:1902749];
regulation of mitochondrial membrane permeability [GO:0046902];
regulation of signal transduction by p53 class mediator [GO:1901796];
regulation of transcription, DNA-templated [GO:0006355];
replicative senescence [GO:0090399];
response to antibiotic [GO:0046677];
response to gamma radiation [GO:0010332];
response to X-ray [GO:0010165];
viral process [GO:0016032]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
chaperone binding [GO:0051087];
chromatin binding [GO:0003682];
copper ion binding [GO:0005507];
core promoter sequence-specific DNA binding [GO:0001046];
damaged DNA binding [GO:0003684];
DNA binding [GO:0003677];
double-stranded DNA binding [GO:0003690];
enzyme binding [GO:0019899];
histone acetyltransferase binding [GO:0035035];
identical protein binding [GO:0042802];
p53 binding [GO:0002039];
protease binding [GO:0002020];
protein heterodimerization activity [GO:0046982];
protein kinase binding [GO:0019901];
protein N-terminus binding [GO:0047485];
protein phosphatase 2A binding [GO:0051721];
protein phosphatase binding [GO:0019903];
protein self-association [GO:0043621];
receptor tyrosine kinase binding [GO:0030971];
RNA polymerase II transcription factor activity, sequence-specific DNA binding [GO:0000981];
RNA polymerase II transcription factor binding [GO:0001085];
sequence-specific DNA binding [GO:0043565];
transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding [GO:0001228];
transcription factor activity, sequence-specific DNA binding [GO:0003700];
transcription factor binding [GO:0008134];
transcription regulatory region DNA binding [GO:0044212];
ubiquitin protein ligase binding [GO:0031625];
zinc ion binding [GO:0008270]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829];
endoplasmic reticulum [GO:0005783];
mitochondrial matrix [GO:0005759];
mitochondrion [GO:0005739];
nuclear chromatin [GO:0000790];
nuclear matrix [GO:0016363];
nucleolus [GO:0005730];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
PML body [GO:0016605];
protein complex [GO:0043234];
replication fork [GO:0005657]
Protein-protein interaction113010
Phylogenetic treeP04637
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.3278926678122740.3172859029847390.437123686452101
AZA vs. DISU0.07096276253263080.7793343992315260.976444104025318
AZA vs. IL70.2488584814971850.1967650074346460.961062526591839
AZA vs. SAHA-0.8611594564602520.0005120072478369540.01303715752347
DISU vs. CD3-0.2685885594174280.4584794883304750.5877802183274
DISU vs. IL70.168230981356390.5059221977326780.830044367655729
DISU vs. SAHA-0.9299216036878540.001792643502717240.0311973790178424
DMSO vs. AZA-0.02350010638971810.8888649053305731
DMSO vs. CD3-0.3613246791878430.2604733090406230.367625107803727
DMSO vs. DISU-0.09592235875002880.6953244719974480.958674191480009
DMSO vs. IL70.279471044562150.1209048847907370.612498791723995
DMSO vs. SAHA-0.8436293646686280.0004054164344917680.00941453171683425
HIV vs. Mock in Activation0.2254113913111080.7170732246740980.999983755607037
HIV vs. Mock in Latency0.07054631845788140.6700331030128740.999834320637052
IL7 vs. CD3-0.07304181719297440.8207379959117150.883452389657737
SAHA vs. CD3-1.211980184441410.0008291073957140680.00304673212714241
SAHA vs. IL7-1.112187330579136.90740655284738e-060.000228338259600047
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
-0.497 0.01208

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.587862 0.000305467
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
1.054 1.637 1.675 1.802 1.976
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB05404 AZD 3355 investigational unknown unknown
DB08363 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine experimental unknown unknown
DB00945 Acetylsalicylic acid approved, vet_approved unknown acetylation

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1A1U NMR - A/C=324-358.
1AIE X-ray 1.5Å A=326-356.
1C26 X-ray 1.7Å A=325-356.
1DT7 NMR - X/Y=367-388.
1GZH X-ray 2.6Å A/C=95-292.
1H26 X-ray 2.2Å E=376-386.
1HS5 NMR - A/B=324-357.
1JSP NMR - A=367-386.
1KZY X-ray 2.5Å A/B=95-289.
1MA3 X-ray 2.0Å B=372-389.
1OLG NMR - A/B/C/D=319-360.
1OLH NMR - A/B/C/D=319-360.
1PES NMR - A/B/C/D=325-355.
1PET NMR - A/B/C/D=325-355.
1SAE NMR - A/B/C/D=319-360.
1SAF NMR - A/B/C/D=319-360.
1SAK NMR - A/B/C/D=319-360.
1SAL NMR - A/B/C/D=319-360.
1TSR X-ray 2.2Å A/B/C=94-312.
1TUP X-ray 2.2Å A/B/C=94-312.
1UOL X-ray 1.9Å A/B=94-312.
1XQH X-ray 1.7Å B/F=369-377.
1YC5 X-ray 1.4Å B=372-389.
1YCQ X-ray 2.3Å B=13-29.
1YCR X-ray 2.6Å B=15-29.
1YCS X-ray 2.2Å A=94-292.
2AC0 X-ray 1.8Å A/B/C/D=94-293.
2ADY X-ray 2.5Å A/B=94-293.
2AHI X-ray 1.8Å A/B/C/D=94-293.
2ATA X-ray 2.2Å A/B/C/D=94-293.
2B3G X-ray 1.6Å B=33-60.
2BIM X-ray 1.9Å A/B=94-312.
2BIN X-ray 1.9Å A=94-312.
2BIO X-ray 1.9Å A=94-312.
2BIP X-ray 1.8Å A=94-312.
2BIQ X-ray 1.8Å A=94-312.
2F1X X-ray 2.3Å A/B=359-368.
2FEJ NMR - A=94-297.
2FOJ X-ray 1.6Å B=361-367.
2FOO X-ray 2.2Å B=358-363.
2GS0 NMR - B=20-73.
2H1L X-ray 3.1Å M/N/O/P/Q/R/S/T/U/V/W/X=92-292.
2H2D X-ray 1.7Å B=372-389.
2H2F X-ray 2.2Å B=372-389.
2H4F X-ray 2.0Å D=372-389.
2H4H X-ray 1.9Å B=372-389.
2H4J X-ray 2.1Å D=372-389.
2H59 X-ray 1.9Å D/E=372-389.
2J0Z NMR - A/B/C/D=326-356.
2J10 NMR - A/B/C/D=326-356.
2J11 NMR - A/B/C/D=326-356.
2J1W X-ray 1.8Å A/B=94-312.
2J1X X-ray 1.6Å A/B=94-312.
2J1Y X-ray 1.6Å A/B/C/D=94-293.
2J1Z X-ray 1.8Å A/B=94-312.
2J20 X-ray 1.8Å A/B=94-312.
2J21 X-ray 1.6Å A/B=94-312.
2K8F NMR - B=1-39.
2L14 NMR - B=13-61.
2LY4 NMR - B=1-93.
2MEJ NMR - B=96-312.
2MWO NMR - B=363-377.
2MWP NMR - B=376-387.
2MWY NMR - B=15-29.
2MZD NMR - B=35-59.
2OCJ X-ray 2.0Å A/B/C/D=94-312.
2PCX X-ray 1.5Å A=94-292.
2RUK NMR - A=41-62.
2VUK X-ray 1.5Å A/B=94-312.
2WGX X-ray 1.7Å A/B=94-312.
2X0U X-ray 1.6Å A/B=94-312.
2X0V X-ray 1.8Å A/B=94-312.
2X0W X-ray 2.1Å A/B=94-312.
2XWR X-ray 1.6Å A/B=89-293.
2YBG X-ray 1.9Å A/B/C/D=94-293.
2YDR X-ray 2.7Å P=144-154.
2Z5S X-ray 2.3Å P/Q/R=15-29.
2Z5T X-ray 2.3Å P/Q/R=15-29.
3D05 X-ray 1.7Å A=94-293.
3D06 X-ray 1.2Å A=94-293.
3D07 X-ray 2.2Å A/B=94-293.
3D08 X-ray 1.4Å A=94-293.
3D09 X-ray 1.9Å A=94-293.
3D0A X-ray 1.8Å A/B/C/D=94-293.
3DAB X-ray 1.9Å B/D/F/H=15-29.
3DAC X-ray 1.8Å B/P=17-37.
3IGK X-ray 1.7Å A=94-293.
3IGL X-ray 1.8Å A=94-293.
3KMD X-ray 2.1Å A/B/C/D=92-291.
3KZ8 X-ray 1.9Å A/B=94-293.
3LW1 X-ray 1.2Å P=385-393.
3OQ5 X-ray 2.5Å D/E=377-386.
3PDH X-ray 1.8Å D=372-389.
3Q01 X-ray 2.1Å A/B=94-356.
3Q05 X-ray 2.4Å A/B/C/D=94-356.
3Q06 X-ray 3.2Å A/B/C/D=96-354.
3SAK NMR - A/B/C/D=319-360.
3TG5 X-ray 2.3Å B=365-375.
3TS8 X-ray 2.8Å A/B/C/D=94-356.
3ZME X-ray 1.3Å A/B=94-312.
4AGL X-ray 1.7Å A/B=94-312.
4AGM X-ray 1.5Å A/B=94-312.
4AGN X-ray 1.6Å A/B=94-312.
4AGO X-ray 1.4Å A/B=94-312.
4AGP X-ray 1.5Å A/B=94-312.
4AGQ X-ray 1.4Å A/B=94-312.
4BUZ X-ray 1.9Å P=379-386.
4BV2 X-ray 3.3Å E/H=376-388.
4HFZ X-ray 2.6Å B/D=15-29.
4HJE X-ray 1.9Å A/B/C/D=92-291.
4IBQ X-ray 1.8Å A/B/C/D=94-293.
4IBS X-ray 1.7Å A/B/C/D=94-293.
4IBT X-ray 1.7Å A/B/C/D=94-293.
4IBU X-ray 1.7Å A/B/C/D=94-293.
4IBV X-ray 2.1Å A=94-293.
4IBW X-ray 1.7Å A=94-293.
4IBY X-ray 1.4Å A/B=94-293.
4IBZ X-ray 1.9Å A/B/C/D=94-293.
4IJT X-ray 1.7Å A=94-293.
4KVP X-ray 1.5Å A/B/C/D=94-312.
4LO9 X-ray 2.5Å A/B/C/D=94-312.
4LOE X-ray 1.8Å A/B/C/D=94-312.
4LOF X-ray 2.0Å A=94-312.
4MZI X-ray 1.2Å A=94-292.
4MZR X-ray 2.9Å A/B/C/D=94-388.
4QO1 X-ray 1.9Å B=92-312.
4RP6 X-ray 1.7Å Z=252-258.
4RP7 X-ray 1.5Å Z=253-258.
4X34 X-ray 1.8Å C/D=377-386.
4XR8 X-ray 2.2Å C/D=94-292.
4ZZJ X-ray 2.7Å B=379-383.
5A7B X-ray 1.4Å A/B=94-312.
5AB9 X-ray 1.3Å A/B=94-312.
5ABA X-ray 1.6Å A/B=94-312.
5AOI X-ray 1.7Å A/B=94-312.
5AOJ X-ray 1.4Å A/B=94-312.
5AOK X-ray 1.3Å A/B=94-312.
5AOL X-ray 1.5Å A/B=94-312.
5AOM X-ray 1.7Å A/B=94-312.
5BUA X-ray 1.8Å A=94-293.
5ECG X-ray 3.0Å A/B=95-312.
5G4M X-ray 1.3Å A/B=94-312.
5G4N X-ray 1.3Å A/B=94-312.
5G4O X-ray 1.4Å A/B=94-312.
5HOU NMR - A=1-61.
5HP0 NMR - A=37-61.
5HPD NMR - A=2-61.
5LAP X-ray 1.4Å A/B=94-312.
5LGY X-ray 2.9Å A/B/C/D=94-291.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope surface glycoprotein gp120 interacts with 15642743
17488272
17488272
Vif stabilizes 21071676
23762317
Vpr regulated by 12573582
15302882
Tat activates 18719392
2435956119604078
Tat upregulates 14595650
24469921
Vpu stabilizes 21521785
Pr55(Gag) interacts with 25653431
Vpr interacts with 15302882
9685344
15142382
15353294
19275583
24744753
integrase induces phosphorylation of 23739328
23739334
24321564
Rev activates 19604078
Nef binds 7853525
11861836
12734410
15078178
Vpr inhibits 16983346
9685344
15142382
Tat cooperates with 11554765
Tat induces acetylation of 22732402
Tat regulated by 18719392
Envelope surface glycoprotein gp120 upregulates 9520163
12404120
14555204
14993250
15155568
15642743
16005638
23202514
Tat downregulates 7777531
9129988
11311202
11554765
19732026
25705251
Vpr activates 11196199
Vif binds 21071676
Nef interacts with 15371598
23847689
Envelope surface glycoprotein gp120 induces 26330555
Envelope surface glycoprotein gp120 induces phosphorylation of 11602639
15033690
1600563819023333
Tat interacts with 15050687
19732026
reverse transcriptase interacts with 11753641
15286711
Tat inhibits 12501250
Vpu upregulates 21521785
Tat inhibited by 25653431
7777531
8207805
19732026
25653431
Tat induces phosphorylation of 20610713
Vpr upregulates 17409234
20097875
23828502
Tat binds 18189286
7818536
18189286
Envelope surface glycoprotein gp120 activates 26330555

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa01522 Endocrine resistance - Homo sapiens (human)
hsa01524 Platinum drug resistance - Homo sapiens (human)
hsa04010 MAPK signaling pathway - Homo sapiens (human)
hsa04071 Sphingolipid signaling pathway - Homo sapiens (human)
hsa04110 Cell cycle - Homo sapiens (human)
hsa04115 p53 signaling pathway - Homo sapiens (human)
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human)
hsa04210 Apoptosis - Homo sapiens (human)
hsa04211 Longevity regulating pathway - Homo sapiens (human)
hsa04310 Wnt signaling pathway - Homo sapiens (human)
hsa04722 Neurotrophin signaling pathway - Homo sapiens (human)
hsa04919 Thyroid hormone signaling pathway - Homo sapiens (human)
hsa05014 Amyotrophic lateral sclerosis (ALS) - Homo sapiens (human)
hsa05016 Huntington's disease - Homo sapiens (human)
hsa05160 Hepatitis C - Homo sapiens (human)
hsa05161 Hepatitis B - Homo sapiens (human)
hsa05162 Measles - Homo sapiens (human)
hsa05166 HTLV-I infection - Homo sapiens (human)
hsa05168 Herpes simplex infection - Homo sapiens (human)
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)
hsa05200 Pathways in cancer - Homo sapiens (human)
hsa05202 Transcriptional misregulation in cancer - Homo sapiens (human)
hsa05203 Viral carcinogenesis - Homo sapiens (human)
hsa05205 Proteoglycans in cancer - Homo sapiens (human)
hsa05206 MicroRNAs in cancer - Homo sapiens (human)
hsa05210 Colorectal cancer - Homo sapiens (human)
hsa05212 Pancreatic cancer - Homo sapiens (human)
hsa05213 Endometrial cancer - Homo sapiens (human)
hsa05214 Glioma - Homo sapiens (human)
hsa05215 Prostate cancer - Homo sapiens (human)
hsa05216 Thyroid cancer - Homo sapiens (human)
hsa05217 Basal cell carcinoma - Homo sapiens (human)
hsa05218 Melanoma - Homo sapiens (human)
hsa05219 Bladder cancer - Homo sapiens (human)
hsa05220 Chronic myeloid leukemia - Homo sapiens (human)
hsa05222 Small cell lung cancer - Homo sapiens (human)
hsa05223 Non-small cell lung cancer - Homo sapiens (human)
hsa05224 Breast cancer - Homo sapiens (human)
hsa05230 Central carbon metabolism in cancer - Homo sapiens (human)
Menu